Evicenter
MarkdownMedical informationP&T meetings
Ifezuntirgene inilparvovec (AMT-130)

Huntington's disease

Manufacturer
uniQure
Launch
Not announced
Last updated
291 sources

Product information and disease descriptionProduct descriptionProduct information

Dosage forms and strengths

4 evidence topics · 4 sources

Pharmaceutical form and route of administration
Pharmaceutical form and concentrations in the European phase Ib/II study
FieldQuoted record
Pharmaceutical form“Solution for infusion”
Concentration, first IMP“2 x 10e12 gc/mL”
Concentration, second IMP“2 x 10e13 gc/mL”
Formulation composition, fill volume, and storage conditions

No evidence found.